Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Background: The biomarkers of immune checkpoint inhibitors (ICIs) efficacy and safety are still urgently needed. As cytokines are easily detected and monitored in circulation, they could be used as potential predictors of response and immune-related adverse events (irAEs) for ICIs therapy. Methods:...

Descripció completa

Dades bibliogràfiques
Autors principals:	Katarina Mirjačić Martinović, Ana Vuletić, Nevena Tišma Miletić, Irina Besu Žižak, Jelena Milovanović, Suzana Matković, Vladimir Jurišić
Format:	Article
Idioma:	English
Publicat:	Elsevier 2023-12-01
Col·lecció:	Translational Oncology
Matèries:	Metastatic melanoma patients BRAF wild type Pembrolizumab Cytokines Monitoring Outcome predictors
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S1936523323001857

Ítems similars

Complete response in a patient with BRAF-mutant metastatic melanoma achieved with the multidisciplinary approach: a case report
per: Hana Garaj, et al.
Publicat: (2024-01-01)

Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
per: Senar Ebinç, et al.
Publicat: (2023-09-01)

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
per: Wu L, et al.
Publicat: (2021-02-01)

Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients
per: Katarina Mirjačić Martinović, et al.
Publicat: (2023-04-01)

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives
per: Dugan MM, et al.
Publicat: (2024-07-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
per: Polsky David, et al.
Publicat: (2004-12-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
per: Francesca Consoli, et al.
Publicat: (2020-07-01)

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study
per: Jacek Calik, et al.
Publicat: (2024-01-01)

Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease
per: Xiang Dan, et al.
Publicat: (2024-04-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
per: I. V. SAMOILENKO, et al.
Publicat: (2017-06-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
per: Ernesto Rossi, et al.
Publicat: (2023-01-01)

A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14C] encorafenib in healthy male subjects
per: Lance Wollenberg, et al.
Publicat: (2023-10-01)

Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
per: Bartoušková Marie, et al.
Publicat: (2020-08-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
per: Justin C. Moser, et al.
Publicat: (2019-12-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
per: Yu. S. Shakh-Paronyants, et al.
Publicat: (2023-03-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
per: Dahlia Fedele, et al.
Publicat: (2024-01-01)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
per: Saba S. Shaikh, et al.
Publicat: (2022-11-01)

Melanoma: BRAFi Rechallenge
per: Christoforos S. Kosmidis, et al.
Publicat: (2023-05-01)

Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naïve and previously infected individuals
per: Milena Cavic, et al.
Publicat: (2023-04-01)

MEK inhibitors for the treatment of NRAS mutant melanoma
per: Sarkisian S, et al.
Publicat: (2018-08-01)

The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome
per: Lazaro Hiram Betancourt, et al.
Publicat: (2021-07-01)

Current State of Target Treatment in BRAF Mutated Melanoma
per: Enrica Teresa Tanda, et al.
Publicat: (2020-07-01)

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report
per: Marco Ghezzi, et al.
Publicat: (2020-03-01)

Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab
per: Rozala Arko, et al.
Publicat: (2022-07-01)

Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations
per: Ahmed Temirak, et al.
Publicat: (2025-02-01)

p53 Promotes Cytokine Expression in Melanoma to Regulate Drug Resistance and Migration
per: Pinakin Pandya, et al.
Publicat: (2022-01-01)

Update on the treatment of BRAFmut metastatic melanoma and future perspectives
per: Peter Mohr, et al.
Publicat: (2025-03-01)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
per: Karam Khaddour, et al.
Publicat: (2021-06-01)

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study
per: Igor V. Samoylenko, et al.
Publicat: (2024-10-01)

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
per: Adi Kartolo, et al.
Publicat: (2022-03-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
per: Simeng Zhang, et al.
Publicat: (2023-01-01)

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report
per: Clara So, et al.
Publicat: (2022-05-01)

Braf protein mutation and its significancy within patients with melanoma
per: Julia Kuchnicka, et al.
Publicat: (2022-08-01)

Treatment of Advanced Melanoma: Past, Present and Future
per: Taku Fujimura, et al.
Publicat: (2020-09-01)

Comparison of Two Rapid Assays for the Detection of <i>BRAF</i> V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes
per: Elodie Long-Mira, et al.
Publicat: (2022-03-01)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
per: Walid Shalata, et al.
Publicat: (2023-02-01)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
per: Nakul Dar, et al.
Publicat: (2023-08-01)

Tyrosine kinase inhibitors via nasogastric tube may resolve severe ileus secondary to melanoma: A case report
per: Lena Groennendijk, et al.
Publicat: (2022-06-01)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
per: Francesco Serra, et al.
Publicat: (2021-08-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
per: O. I. Kit, et al.
Publicat: (2016-06-01)